With clinical trials in sight, ResVita Bio reaches out to Netherton syndrome community
In preparation for future tests of their flagship therapy, the company is offering updates to those afflicted with the disease.
Testing a new treatment in patients is the milestone that biotech startups dream of. That exciting achievement is now in sight for ResVita Bio, a therapeutics company developing topical cell therapies to tackle skin diseases. In preparation for clinical trial recruitment, the company recently released a clinical trial interest form where those suffering from Netherton syndrome — or their guardians or caregivers — can sign up to stay informed about the company’s upcoming clinical trials.
“Now that we have a clear regulatory path toward clinical trials, it’s important to connect with individuals and families who want to stay informed,” said Amin Zargar, Ph.D., ResVita Bio’s CEO. “Our goal is simply to keep the community updated and ensure people are aware when research opportunities become available.”
ResVita Bio, a current tenant here at Bakar Bio Labs, has had an exciting year. The company recently received positive feedback from the FDA at its pre-IND meeting. ResVita Bio’s current treatment, RVB-003, targets the pathways impacted by Netherton syndrome, a potentially fatal chronic skin disease. RVB-003 has already received both Orphan Drug Designation and Rare Pediatric Disease Designation, two FDA designations designed to streamline development for certain therapies.
Zargar says that the company plans to complete its pre-IND studies by the end of Q1 in 2026 and complete manufacturing of its clinical trial therapy by the end of Q2. He aims to start recruiting for clinical trials in 2026 and wrap up recruitment by the end of the summer.
“It’s really amazing, our pre-clinical journey is almost complete,” he says.
In September, Zargar welcomed Chad Miller, Ph.D., a seasoned protein engineer and entrepreneur, as CTO. Miller utilizes deep learning to efficiently engineer potent proteins that precisely target the pathways afflicted by skin diseases. Harmless bacteria engineered to mass-produce these proteins are suspended in a lotion that can be applied directly to affected patches of skin.
Zargar and Miller met at Bakar Bio Labs. At the time, Miller was building Nosis Bio’s protein engineering platform, and the two often exchanged ideas as founders navigating similar challenges.
“There was a world-class protein engineer sitting one cubicle away from me,” Zargar says.
ResVita Bio sees Netherton syndrome as the first of many barrier-compromising skin diseases addressable with its living-cell delivery platform and machine learning-driven protein engineering engine. Using the same modular platform, the company is advancing a pipeline targeting related rare genetic disorders including X-linked ichthyosis, autosomal recessive congenital ichthyosis, ichthyosis vulgaris, Peeling Skin Syndrome, and Chanarin-Dorfman Syndrome.
Recent FDA updates enabling approval based on a “plausible mechanism of action” pathway created a strong regulatory tailwind, allowing ResVita Bio to develop treatments for multiple diseases efficiently under a unified platform strategy.
“Every new protein we develop is a new disease we can tackle,” says Miller. “If we can achieve this for Netherton syndrome, then we can do it for 10 more diseases.”
